Spots Global Cancer Trial Database for triple negative breast cancer (tnbc)
Every month we try and update this database with for triple negative breast cancer (tnbc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of NX-1607 in Adults With Advanced Malignancies | NCT05107674 | Ovarian Cancer,... Gastric Cancer GastroEsophagea... Head and Neck S... Metastatic or U... Non-small Cell ... Metastatic Cast... Malignant Pleur... Triple Negative... Metastatic Urot... Cervical Cancer Diffuse Large B... Richter Transfo... Microsatellite ... | NX-1607 Paclitaxel | 18 Years - | Nurix Therapeutics, Inc. | |
| Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer | NCT02833766 | Breast Cancer | anti-EGFR-IL-do... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | NCT02178722 | Microsatellite-... Endometrial Can... Head and Neck C... Hepatocellular ... Gastric Cancer Lung Cancer Lymphoma Renal Cell Carc... Ovarian Cancer Solid Tumors UC (Urothelial ... Melanoma Bladder Cancer Triple Negative... | MK-3475 INCB024360 | 18 Years - | Incyte Corporation | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Expanded Access to Veliparib | NCT03123211 | Solid Tumors Wi... Triple Negative... High Grade Sero... Patients Requir... | Veliparib | - | AbbVie | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | NCT02819518 | Triple Negative... | Pembrolizumab Nab-paclitaxel Paclitaxel Gemcitabine Carboplatin Normale Saline ... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | NCT03098550 | Advanced Cancer | Nivolumab Daratumumab | 18 Years - | Bristol-Myers Squibb | |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | NCT03549000 | Non-small Cell ... Triple Negative... Pancreatic Duct... Colorectal Canc... Ovarian Cancer Renal Cell Carc... Metastatic Cast... | NZV930 PDR001 NIR178 | 18 Years - | Novartis | |
| Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT05555706 | Triple Negative... | B013+Nab-Paclit... | 18 Years - 75 Years | Shanghai Jiaolian Drug Research and Development Co., Ltd | |
| A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | NCT03746431 | Advanced Solid ... Endometrial Can... Cervical Cancer Ovarian Cancer Breast Cancer Triple Negative... HER2-negative B... Head and Neck S... Adrenocortical ... Uveal Melanoma | [111In]-FPI-154... [225Ac]-FPI-143... FPI-1175 Infusi... [225Ac]-FPI-143... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT05555706 | Triple Negative... | B013+Nab-Paclit... | 18 Years - 75 Years | Shanghai Jiaolian Drug Research and Development Co., Ltd | |
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | NCT03961698 | Breast Cancer Renal Cell Carc... | IPI-549 (eganel... Atezolizumab nab-paclitaxel Bevacizumab | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | NCT02178722 | Microsatellite-... Endometrial Can... Head and Neck C... Hepatocellular ... Gastric Cancer Lung Cancer Lymphoma Renal Cell Carc... Ovarian Cancer Solid Tumors UC (Urothelial ... Melanoma Bladder Cancer Triple Negative... | MK-3475 INCB024360 | 18 Years - | Incyte Corporation | |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | NCT05891171 | Advanced Cancer Advanced Malign... Bladder Cancer Cervical Cancer Esophageal Canc... Gastric Cancer Gastroesophagea... Head and Neck S... Non-Small Cell ... Ovarian Cancer Renal Cell Carc... Triple Negative... | AB598 Zimberelimab Carboplatin Pemetrexed Fluorouracil Leucovorin Oxaliplatin | 18 Years - | Arcus Biosciences, Inc. | |
| A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | NCT03098550 | Advanced Cancer | Nivolumab Daratumumab | 18 Years - | Bristol-Myers Squibb | |
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | NCT02698176 | NUT Midline Car... Triple Negative... Non-small Cell ... Castration-resi... | Birabresib | 18 Years - | Merck Sharp & Dohme LLC | |
| Breast Cancer Study of Preoperative Pembrolizumab + Radiation | NCT03366844 | Breast Cancer | Pembrolizumab RT Boost | 18 Years - | Cedars-Sinai Medical Center | |
| Breast Cancer Study of Preoperative Pembrolizumab + Radiation | NCT03366844 | Breast Cancer | Pembrolizumab RT Boost | 18 Years - | Cedars-Sinai Medical Center | |
| Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | NCT06189209 | Triple Negative... | Tenalisib | 18 Years - | Rhizen Pharmaceuticals SA | |
| Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer | NCT05088057 | Triple Negative... | Camrelizumab Doxorubicin Cyclophosphamid... Docetaxel | 18 Years - 70 Years | Jilin University | |
| A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | NCT05888831 | Advanced Solid ... | BMS-986449 Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) | NCT03855358 | Triple Negative... | TQB2450 Injecti... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) | NCT03855358 | Triple Negative... | TQB2450 Injecti... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | NCT02158507 | Metastatic Trip... | Combination of ... | 19 Years - | University of Alabama at Birmingham | |
| A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | NCT04225117 | Locally Advance... | enfortumab vedo... pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases | NCT02048059 | Breast Cancer Brain Metastase... | ANG1005 | 18 Years - | Angiochem Inc | |
| A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03071757 | Advanced Solid ... | ABBV-368 ABBV-181 | 18 Years - | AbbVie | |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | NCT03554109 | Triple Negative... | Leucovorin 5-Fluorouracil Aldoxorubicin H... nab-Paclitaxel ETBX-011 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 Avelumab ALT-803 haNK Cyclophosphamid... Doxorubicin HCL paclitaxel | 18 Years - | ImmunityBio, Inc. | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie | |
| A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03071757 | Advanced Solid ... | ABBV-368 ABBV-181 | 18 Years - | AbbVie | |
| Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer | NCT05088057 | Triple Negative... | Camrelizumab Doxorubicin Cyclophosphamid... Docetaxel | 18 Years - 70 Years | Jilin University | |
| A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) | NCT05068141 | Triple Negative... | SG001 Nab-paclitaxel | 18 Years - 70 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors | NCT03821935 | Advanced Solid ... | Livmoniplimab Budigalimab | 18 Years - | AbbVie | |
| OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | NCT05949021 | Triple Negative... | Combination of ... | - | Rutgers, The State University of New Jersey |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
